Published Paper Details:

Abstract: A novel, precise, and accurate reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous estimation of Dapagliflozin and Linagliptin in bulk drug and pharmaceutical formulation. The chromatographic separation was achieved using a C18 column with a mobile phase consisting of [Mobile Phase Composition] at a flow rate of [Flow Rate]. The detection wavelength was set at [Detection Wavelength]. The method was validated according to ICH guidelines, and the results showed good linearity, accuracy, precision, and specificity. The retention times for Dapagliflozin and Linagliptin were found to be [Retention Time] and [Retention Time], respectively. The percentage recovery for both drugs was within the acceptable limits. The developed method was successfully applied to the analysis of Dapagliflozin and Linagliptin in pharmaceutical formulation, and the results were in good agreement with the label claim. The proposed method can be used for routine quality control analysis of these drugs in pharmaceutical industries. The developed method is simple, rapid, and cost-effective, making it suitable for routine quality control analysis in pharmaceutical industries. The method's specificity, accuracy, and precision ensure reliable quantification of Dapagliflozin and Linagliptin, supporting its use in pharmaceutical development and quality control.